Literature DB >> 3006680

Peroxidative free radical formation and O-demethylation of etoposide(VP-16) and teniposide(VM-26).

N Haim, J Roman, J Nemec, B K Sinha.   

Abstract

The peroxidative activation of the antitumor drugs, etoposide (VP-16) and teniposide (VM-26), has been studied in vitro. Both of these drugs, in the presence of horseradish peroxidase or prostaglandin synthetase, formed phenoxy radical intermediates. Furthermore, this activation also resulted in the formation of two metabolites from each of the drugs. Using HPLC and mass spectrometry, one of the metabolites was shown to be the reactive o-quinone derivative of the parent drug which resulted from the peroxidative O-demethylation. It appears that O-demethylation catalyzed by peroxidases may be an important mechanism for the formation of reactive intermediates and may play a role in the mechanism of action of VP-16 and VM-26.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3006680     DOI: 10.1016/0006-291x(86)90965-4

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  17 in total

Review 1.  Etoposide and teniposide. Bioanalysis, metabolism and clinical pharmacokinetics.

Authors:  J J Holthuis
Journal:  Pharm Weekbl Sci       Date:  1988-06-17

2.  Etoposide quinone is a redox-dependent topoisomerase II poison.

Authors:  David A Jacob; Susan L Mercer; Neil Osheroff; Joseph E Deweese
Journal:  Biochemistry       Date:  2011-06-02       Impact factor: 3.162

3.  Effect of nitric oxide on the anticancer activity of the topoisomerase-active drugs etoposide and adriamycin in human melanoma cells.

Authors:  Birandra K Sinha; Ashutosh Kumar; Suchandra Bhattacharjee; Michael G Espey; Ronald P Mason
Journal:  J Pharmacol Exp Ther       Date:  2013-09-18       Impact factor: 4.030

4.  Etoposide pathway.

Authors:  Jun Yang; Alessia Bogni; Erin G Schuetz; Mark Ratain; M Eileen Dolan; Howard McLeod; Li Gong; Caroline Thorn; Mary V Relling; Teri E Klein; Russ B Altman
Journal:  Pharmacogenet Genomics       Date:  2009-07       Impact factor: 2.089

Review 5.  Pharmacokinetic optimisation of treatment with oral etoposide.

Authors:  Giuseppe Toffoli; Giuseppe Corona; Barbara Basso; Mauro Boiocchi
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

6.  Antitumor agents. 126. Novel 4 beta-substituted anilino derivatives of 3',4'-O,O-didemethylpodophyllotoxin as potent inhibitors of human DNA topoisomerase II.

Authors:  Z Q Wang; Y C Shen; H X Chen; J Y Chang; X Guo; Y C Cheng; K H Lee
Journal:  Pharm Res       Date:  1993-03       Impact factor: 4.200

Review 7.  Topoisomerase II and leukemia.

Authors:  Maryjean Pendleton; R Hunter Lindsey; Carolyn A Felix; David Grimwade; Neil Osheroff
Journal:  Ann N Y Acad Sci       Date:  2014-02-03       Impact factor: 5.691

8.  Synergistic enhancement of topotecan-induced cell death by ascorbic acid in human breast MCF-7 tumor cells.

Authors:  Birandra K Sinha; Thomas J van 't Erve; Ashutosh Kumar; Carl D Bortner; Ann G Motten; Ronald P Mason
Journal:  Free Radic Biol Med       Date:  2017-10-24       Impact factor: 7.376

Review 9.  Recent progress on C-4-modified podophyllotoxin analogs as potent antitumor agents.

Authors:  Ying-Qian Liu; Jing Tian; Keduo Qian; Xiao-Bo Zhao; Susan L Morris-Natschke; Liu Yang; Xiang Nan; Xuan Tian; Kuo-Hsiung Lee
Journal:  Med Res Rev       Date:  2014-05-14       Impact factor: 12.944

10.  IS METABOLIC ACTIVATION OF TOPOISOMERASE II POISONS IMPORTANT IN THE MECHANISM OF CYTOTOXICITY?

Authors:  Birandra K Sinha; Ronald P Mason
Journal:  J Drug Metab Toxicol       Date:  2015-07-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.